BioSpace News Archive

NeuX Technologies , a leading provider of advanced medical technology for the health, wellness, fitness and human performance markets, is excited to announce Dr. Tim Brown has joined NeuX as Chief Innovation Officer.

Lyndra Therapeutics today announced results from a preclinical study on LYN-013, the company’s oral, ultra-long-acting, extended-release (ER) buprenorphine capsule, in development for the weekly treatment of opioid use disorder (OUD).

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its ongoing Phase 2 clinical trials of VIR-2218 and ongoing Phase 1 studies of VIR-3434 in patients with chronic hepatitis B virus (HBV) infection.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that the Committee for Orphan Medicinal Products (“COMP”) of the European Medicines Agency (“EMA”) has recommended the granting of orphan medicinal product designation (“OMPD”) in the European Union (“EU”) for 177Lu-omburtamab-DTPA for the treatment of medulloblastoma.

The American Diabetes Association® is highlighting the latest understanding of how to address health disparities laid bare by the pandemic at the virtual 81st Scientific Sessions.

Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Isotretinoin Capsules.

Multisystem Inflammatory Syndrome in Children (MIS-C) significantly affected more Black and Latino children than white children, with Black children at the highest risk, according to a new observational study of 124 pediatric patients treated at Children’s National Hospital in Washington, D.C.

Indago, a medical device and technology company, announces the successful close of its $10 million convertible note round of financing.

Abbott (NYSE: ABT) today announced late-breaking data that showed FreeStyle Libre, the world’s leading7 continuous glucose monitoring (CGM) system, can support health equity through access to more affordable, life-changing technology for Americans living with diabetes, including those in underserved communities.

Proteomics International Laboratories Ltd announces testing for diabetic kidney disease with the PromarkerD prognostic blood test could save US payers almost USD400 billion over 10 years, research suggests.